Testing to Target in Non-Small Cell Lung Cancer: Managed Care Perspectives

August 18, 2016

Recent advancements in the scientific knowledge of non-small cell lung cancer (NSCLC) pathology have shifted the paradigm of care from a “one-size fits all” regimen, to one that focuses on individualized therapy and integrating biomarker-targeted therapies into treatment paradigms. The number of approved and emerging NSCLC targeted therapies tops a dozen. These new cancer agents contribute substantially to improved outcomes for patients as well as rising healthcare costs. Experts indicate that the key to providing cost-effective care is to better match patients with specifically targeted treatment options.

This live webcast will highlight the latest clinical evidence about the role of genetic and molecular targets in developing personalized treatment plans for patients with NSCLC, with a special focus on opportunities for managed care and specialty pharmacists to facilitate individualized care. Expert faculty will offer insights on evolving best practices for biomarker testing and interpretation to optimize therapy choice, recent data from the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, and the pharmacoeconomic implications of biomarker-directed NSCLC management.
 

GOAL
Managed care and specialty pharmacists will gain new skills in assessing biomarker results and developing treatment plans based on the presence of drug-actionable targets in NSCLC, as well as new strategies for supporting the safe, effective, and evidence-based use of targeted therapies, thus optimizing pharmaceutical care.

Target Audience

This activity is designed for managed care and specialty pharmacists. No prerequisites required.

Learning Objectives

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
 

  • ASSESS the role of genetic and molecular biomarkers in guiding NSCLC treatment plans.
  • EVALUATE the safety, efficacy, and therapeutic role of new and emerging targeted therapies.
  • RECOMMEND pharmacy-driven strategies to facilitate individualized NSCLC management.
Additional information
Credit Designation Statement: 


The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.5 live contact hours credit (0.15 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. Immediate download of statement of CE credit will be available after successful completion of the educational activity. CE credit will be submitted to the NABP CE Monitor within 30 days. UAN: 0064-0000-16-212-L01-P.

It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Internet CME Policy: 
POLICY ON FACULTY AND PROVIDER DISCLOSURE
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.
AMERICANS WITH DISABILITIES ACT (ADA)
The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.
GRIEVANCE POLICY
A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
FEE INFORMATION
There is no fee for this educational activity.
Course summary
Available credit: 
  • 1.50 ACPE
Course opens: 
08/10/2016
Course expires: 
08/18/2016
Event starts: 
08/18/2016 - 9:00pm
Event ends: 
08/18/2016 - 10:30pm
Rating: 
0

R. Donald Harvey, PharmD, FCCP, BCOP (Course Director)
Associate Professor, Hematology/Medical Oncology
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia

Matthew Farber, MA
Senior Director
Oncology Disease State
Walgreens Specialty Pharmacy
Deerfield, Illinois

Available Credit

  • 1.50 ACPE

Accreditation Period

Course opens: 
08/10/2016
Course expires: 
08/18/2016
Please login or register to take this course.